The concern for DKA in patients with T1DM treated with SGLT-2i was addressed by the International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated WithSodium–Glucose Cotransporter (SGLT) Inhibitors [71] which recommended an appropriate patient selection for this therapy, continuous ketone monitoring, insulin dose adjustments with caution in reducing daily doses, or discontinuation of SGLT-2i if ketones persist or are in high levels [173,174]. This evidence concerns the gene INS and diabetic ketoacidosis.